Tumor Necrosis Factor-, human (hTNF-) 11371843001

Recombinant tumor necrosis factor-, human (hTNF-), is produced in E. coli and purified by standard chromatographic techniques. Its primary structure is composed of one polypeptide chain (158 amino acids), identical to natural hTNF- (157 amino acids) but with an extra methionine at the amino-terminus.
The TNFA (tumor necrosis factor ) gene is mapped to human chromosome 6p21.33 and codes for a pro-inflammatory cytokine.
Specificity
Human TNF- is effective on mouse and human cells.
Human TNF-a is produced by activated monocytes and macrophages. Human TNF-a has been highly purified and found to have a molecular weight of 17,000 Da (SDS-PAGE). Under nondenaturing conditions, hTNF-a has a molecular weight of approximately 45,000 Da, suggesting that the native protein associates in an oligomeric form.
hTNF-a causes selective necrosis of murine tumors when injected into tumor bearing mice. In vitro hTNF-a has direct cytolytic or cytostatic activity on certain transformed cells. In this context it acts synergistically with interferon-.
Cytotoxicity of hTNF-a for tumor cells has been reported since the initial description of this factor. It has been recognized that hTNF-a also has important effects on several types of normal cells and may have profound effects on inflammatory reactions, bone resorption, the development and function of granulocytes, hemostasis and lipid metabolism (in this context hTNF-a is also known as cachectin). It has also potent antiviral activity in vitro.
Human TNF- (tumor necrosis factor ) is produced by activated monocytes and macrophages.
hTNF- causes selective necrosis of murine tumors when injected into tumor-bearing mice. In vitro, hTNF- has direct cytolytic or cytostatic activity on certain transformed cells. In this context, it acts synergistically with interferon-. hTNF- also has activating and growth stimulating activities on a variety of normal cells and has antiviral enhancing activity on many cell types in vitro. It has been reported in research studies that in vivo hTNF- can cause the necrosis of certain tumors.
Tumor Necrosis Factor-, human (hTNF-) has been used to study the role of ZnO in the regulation of inflammatory responses of vascular endothelial cells via NF-B (nuclear factor-B) signaling. It has also been used to study the its role as a regulator of perlecan production in prostate cancer cells. The TNFA gene is significantly associated with the regulation of innate and adaptive immune responses. Polymorphism of TNFA gene is known to cause acute motor axonal neuropathy. The cytokine release and gene action is associated with epithelial cells, myeloid cells, endothelial, as well as tumor cells. Tumor cells are known to release TNFA, specifically in response to chemotherapy.
Features and Benefits
Growth Enhancement
CCD-18Co (normal human colon)
Detroit 551 (normal human fetal skin)
FS-4 (normal human foreskin)
FS-48 (normal human foreskin)
LL24 (normal human lung)
NRK-49F (normal rat kidney)
Osteoclasts
WI138 (normal human fetal lung)
WI-1003 (normal human lung)

Null response
A549 (human lung carcinoma)
B16 (murine melanoma)
B16F10 (murine melanoma)
Calu-3 (human lung carcinoma)
CMT-93 (murine rectal carcinoma)
G-361 (human melanoma)
HeLa (human cervical carcinoma)
HeLa D98 (human cervical carcinoma)
HT-29 (human colon carcinoma)
HT1080 (human fibrosarcoma)
KB (human oral epidermoid carcinoma)
LS174T (human colon carcinoma)
RD (human rhabdosarcoma)
Saos-2 (human osteogenic sarcoma)
SK-CO-1 (human colon carcinoma)
SK-LU-1 (human lung carcinoma)
SK-OV-3 (human ovarian carcinoma)
SK-UT-1 (human uterine carcinoma)
S49 (murine lymphoma)
T24 (human bladder carcinoma)
WI138 VA 13 (human transformed W138)
Antiproliferative response
BT-20 (human breast carcinoma)
BT-475 (human breast carcinoma)
B6MS2 (murine sarcoma)
B6MS5 (murine sarcoma)
CMS4 (murine sarcoma)
CMS16 (murine sarcoma)
L929 (murine fibroblast)
MCF7 (human breast carcinoma)
ME-180 (human cervical carcinoma)
Meth A (murine sarcoma)
MMT (murine breast carcinoma)
SAC (Moloney-transformed murine 3T3)
SK-MEL-109 (human melanoma)
SK-OV-4 (human ovarian carcinoma)
UV1591-RE (murine fibrosarcoma)
WEHI-164 (murine sarcoma)
WiDr (human colon carcinoma)
Sequence
One polypeptide chain (158 amino acids), identical to natural hTNF-α (157 amino acids), however, it has an extra methionine at the amino-terminus.
Chain Length 158 AA
Unit Definition
EC50 definition: The amount of hTNF- that is required to mediate half-maximal cytotoxicity (MTT cleavage) with WEHI 164 cells in the presence of actinomycin D (1 unit equals 0.01 ng/ml).
Physical form
10 μg/ml solution in PBS and 1 mg/ml BSA, filtered through a 0.2 μm pore size membrane.
Preparation Note
Working concentration: 1 ng/ml
For complete cell lysis of sensitive cell lines about 1 ng/ml is recommended.
Working solution: Dilute the concentrated hTNF- solution (10 µg/ml) with PBS or culture medium containing BSA (or HSA), 1 mg/ml (0.1%) or serum 1-10%.
Storage conditions (working solution): -15 to -25 °C
The solution ca be stored in aliquots at -15 to -25 °C.
For life science research only. Not for use in diagnostic procedures. The biological activity of this product may vary in different in vitro applications. We recommend to determine the optimal concentration range for specific applications.

Quality Level	100
biological source	human
recombinant	expressed in E. coli
assay	>98% (SDS-PAGE)
form	solution
potency	0.01 ng/mL EC50
specific activity	1.0*10^8 U/mg
mol wt	17000 Da
packaging	pkg of 1,000,000 U (10 µg, 1 ml)
Торговая марка	Roche
storage condition	avoid repeated freeze/thaw cycles
impurities	<0.1 EU/µgtested (LAL test)
UniProt accession no.	Q9UBM5,
shipped in	dry ice
storage temp.	20°C
Gene Information	human ... TNF(7124)

RIDADR	NONH for all modes of transport
WGK Germany	nwg
Flash Point F	does not flash
Flash Point C	does not flash